Analogy of Kaba Suram with COVID-19 Symptoms - A Siddha Literature Review
Kaba Suram (phlegmatic fever) is one among the 64 types of Suram (Pyrexia/fever), its synonyms, causes, pathology and characteristics have been mentioned crystal clear in Siddha literature. Its clinical features have been mentioned in few literatures such as Theran karisal, Suravagadam, Yugi chinthamani etc., which are almost similar to each other. The present day pandemic disease COVID-19 which still lacks specific drug towards its management or prophylaxis has become the spectrum of research focus in current scenario. Upon keen understanding of the Siddha literature the signs and symptoms of Kaba Suram fall in line with COVID-19 and a few other flu like illnesses. Therefore, the herbal decoction Kaba Sura Kudineer (KSK) indicated for the management of Kaba Suram has been recommended by the Siddha research community towards an integrated approach in tackling this worldwide emergency. The current scientific community demands evidence based explanation to understand the concept of Siddha system of medicine and necessitates International standards to reassure the efficacy of Siddha medicine. In this aspect, this review is aimed at evaluating all the available informations on Kaba Suram in Siddha literature and pathophysiology of COVID-19 and to interpret the search results in terms of pathophysiology of Kaba Suram based on Mukkutram theory. This effort would therefore enable the Siddha research community to opt for effective Siddha medicines to manage the present pandemic situation.
Copyright (c) 2020 International Journal of Ayurvedic Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
The author hereby transfers, assigns, or conveys all copyright ownership to the International Journal of Ayurvedic Medicine (IJAM). By this transfer, the article becomes the property of the IJAM and may not be published elsewhere without written permission from the IJAM.
This transfer of copyright also implies transfer of rights for printed, electronic, microfilm, and facsimile publication. No royalty or other monetary compensation will be received for transferring the copyright of the article to the IJAM.
The IJAM, in turn, grants each author the right to republish the article in any book for which he or she is the author or editor, without paying royalties to the IJAM, subject to the express conditions that (a) the author notify IJAM in advance in writing of this republication and (b) a credit line attributes the original publication to IJAM.